Journal ArticleDOI
91 Sustained Therapeutic Benefit of Vedolizumab Throughout 1 Year in Crohn's Disease in Gemini II, a Randomized, Placebo-Controlled, Double-Blind, Multicenter Study
Paul Rutgeerts,William J. Sandborn,Walter Reinisch,Jing Xu,Catherine Milch,Irving H. Fox,Michael Smyth +6 more
Reads0
Chats0
TLDR
Treatment with LAQ is well tolerated and the 0.5 and 1 mg doses may have clinically relevant effects on remission & response, and all doses were found to reduce objective measures of intestinal inflammation in active CD.About:
This article is published in Gastroenterology.The article was published on 2013-05-01. It has received 2 citations till now. The article focuses on the topics: Calprotectin & Placebo.read more
Citations
More filters
Journal ArticleDOI
Novedades sobre los tratamientos para la enfermedad inflamatoria intestinal
TL;DR: Diversos estudios han comparado el infliximab y the ciclosporina en la colitis ulcerosa corticorrefractaria en practica clinica, aportando informacion complementaria a la del ensayo clinico CYSIF.
Related Papers (5)
Phase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn's disease: report of the OPERA study.
William J. Sandborn,Scott D. Lee,Dino Tarabar,Edouard Louis,Maria Kłopocka,Jochen Klaus,Walter Reinisch,Xavier Hébuterne,Dong Il Park,Stefan Schreiber,Satyaprakash Nayak,Alaa Ahmad,Anindita Banerjee,Lisa S. Brown,Fabio Cataldi,Kenneth J. Gorelick,John B. Cheng,Mina Hassan-Zahraee,Clare Robert A,Geert R. D'Haens +19 more